Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Ralf Amann

Deputy Head of Medical Biotechnology Division | Head of Virus-based Therapies

Fraunhofer Institute for Interfacial Engineering and Biotechnology

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Articles (15)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (7)

Sabine Bélard

Professor

University of Tübingen

GERMANY

View details

Michael W. Wolff

University of Applied Sciences Mittelhessen

GERMANY

View details

Alex Gómez Calvo

Personal investigador docente

Universidad de Zaragoza

SPAIN

View details

Friederike Eilts

Fraunhofer Institute for Interfacial Engineering and Biotechnology

GERMANY

View details

Daniel Pinschewer

Professor at University of Basel

University of Basel

SWITZERLAND

View details

Benhur Lee

Professor (Ward-Coleman Chair)

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Ignacio de Blas

Profesor Titular

Universidad de Zaragoza

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ralf Amann

Research Interests

Explore related searches

Articles (15)

In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines

Orf virus-based vectors induce potent germinal center B cell, Tfh cell and CD8<sup>+</sup> T cell responses.

Heterologous ORFV–Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike

Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice

Commentary on ‘Confounding Variable in Recent Clinical Trial on ORFV‐Based Therapeutics’

Advancing ORFV‐Based Therapeutics to the Clinical Stage

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2

Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development

Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats

An investigation of excipients for a stable Orf viral vector formulation

Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus

Collaborators (7)

Sabine Bélard

Michael W. Wolff

Alex Gómez Calvo

Friederike Eilts

Daniel Pinschewer

Benhur Lee

Ignacio de Blas

Make your next move.

Ralf Amann

Research Interests

Explore related searches

Articles (15)

In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines

Orf virus-based vectors induce potent germinal center B cell, Tfh cell and CD8&lt;sup&gt;+&lt;/sup&gt; T cell responses.

Heterologous ORFV–Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike

Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice

Commentary on ‘Confounding Variable in Recent Clinical Trial on ORFV‐Based Therapeutics’

Advancing ORFV‐Based Therapeutics to the Clinical Stage

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2

Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development

Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats

An investigation of excipients for a stable Orf viral vector formulation

Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus

Collaborators (7)

Sabine Bélard

Michael W. Wolff

Alex Gómez Calvo

Friederike Eilts

Daniel Pinschewer

Benhur Lee

Ignacio de Blas

Make your next move.

Orf virus-based vectors induce potent germinal center B cell, Tfh cell and CD8<sup>+</sup> T cell responses.